THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
110.55%
Total 13F principal
$80,940,950
Principal change
-$141,505,617
Total reported market value
$89,502,134
Number of holders
17
Value change
-$157,659,342
Number of buys
5
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q1 2022

As of 31 Mar 2022, THERAVANCE INC - CORPORATE OBLIG was held by 17 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $80,940,950 in principal (par value) of the bond. The largest 10 bondholders included LAZARD ASSET MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., BANK OF AMERICA CORP /DE/, DEUTSCHE BANK AG\, CSS LLC/IL, TORONTO DOMINION BANK, PALISADE CAPITAL MANAGEMENT LLC/NJ, SSI INVESTMENT MANAGEMENT LLC, and WELLS FARGO & COMPANY/MN. This page lists 17 institutional bondholders reporting positions for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.